



ASX Announcement

24 March 2020

Creso Pharma brings to the market new CBD Hemp Teas to support the immune system

Highlights

- Creso Pharma has developed a new microgranulated instant cannaQIX® CBD instant hemp tea as an expansion of its cannaQIX® human health product line
- This new product was developed together with Switzerland's Domaco Pharma based on the anibidiol® granules technology
- The new cannaQIX® CBD instant hemp tea has been conceived with CBD combined anti-viral herbs in support of strengthening the immune system
- Creso Pharma produces and markets the cannaQIX® products in collaboration with commercial partners in different countries

Creso Pharma Limited (ASX:CPH, FRA:1X8) ('Creso Pharma' or 'the Company') is pleased to announce that its first cannaQIX® CBD instant hemp tea will be available on the international markets in Q3. The Company has successfully developed and tested its first CBD hemp instant tea. The technological breakthrough will be used to extend the Company's successful cannaQIX® product line.

The cannaQIX® CBD instant hemp tea has been developed based on the anibidiol® granules technology. cannaQIX® CBD instant hemp tea is offered in two product versions:

- cannaQIX® CBD instant hemp tea formulated with CBD hemp, zinc, selene, elderberry, and vitamins to support the immune system and manage stress
- cannaQIX® NITE CBD instant hemp tea formulated with CBD hemp, zinc, selene, elderberry, lemon balm and vitamins to strengthen the immune system and support better sleep



cannaQIX® Instant Hemp Tea



cannaQIX® NITE Instant Hemp Tea

These new products use natural hemp plant and provide an “entourage effect” in which various compounds work together to particularly strengthen the immune system. The entourage effect has received considerable attention in the cannabis industry. It is also a critical factor in the food and beverage industry where multiple different molecules co-create a person’s perception of taste, smell, mouthfeel, and other sensations.

Creso Pharma plans to distribute the new products with different commercial partners in several countries and expects that the products will be ready for launch in Q3 2020.

Dr. Miri Halperin Wernli, Co-Founder and CEO of Creso Pharma said: “We are looking forward to entering new and existing markets with our new cannaQIX® CBD instant hemp teas, as there is an increasing demand for easy to use natural products to help strengthen the immune system, particularly given the challenging healthcare times we are facing”.

Dr. Gian Trepp, R&D/Commercial Director of Creso Pharma said: “With the achievement of this innovation we address customers’ needs for a natural easy to use product to support the immune system.”

Ends

Authority and Contact Details

This announcement has been authorised for release by Dr Miri Halperin Wernli, CEO and Managing Director of Creso Pharma Limited.



For further information, please contact:

Investor Enquiries

EverBlu Capital

E: info@everblucapital.com

P: +61 2 8249 0000

Media Enquiries

Julia Maguire | The Capital Network

E: julia@thecapitalnetwork.com.au

P: +61 419 815 386

About Creso Pharma

Creso Pharma Limited (ASX:CPH) brings the best of cannabis to better the lives of people and animals. It brings pharmaceutical expertise and methodological rigor to the cannabis world and strives for the highest quality in its products. It develops cannabis and hemp derived therapeutic, nutraceutical, and life style products with wide patient and consumer reach for human and animal health. Creso Pharma uses GMP (Good Manufacturing Practice) development and manufacturing standards for its products as a reference of quality excellence with initial product registrations in Switzerland. It has worldwide rights for a number of unique and proprietary innovative delivery technologies which enhance the bioavailability and absorption of cannabinoids. To learn more please visit: www.cresopharma.com

Forward Looking statements

This announcement contains forward-looking statements with respect to Creso and its respective operations, strategy, investments, financial performance and condition. These statements generally can be identified by use of forward-looking words such as "may", "will", "expect", "estimate", "anticipate", "intends", "believe" or "continue" or the negative thereof or similar variations.

The actual results and performance of Creso could differ materially from those expressed or implied by such statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Some important factors that could cause actual results to differ materially from expectations include, among other things, general economic and market factors, competition and government regulation.

The cautionary statements qualify all forward-looking statements attributable to Creso and persons acting on its behalf. Unless otherwise stated, all forward-looking statements speak only as of the date of this announcement and Creso has no obligation to up-date such statements, except to the extent required by applicable laws.